Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB)

Vaccine. 2022 Oct 12;40(43):6206-6210. doi: 10.1016/j.vaccine.2022.09.056. Epub 2022 Sep 26.


While in Switzerland, pneumococcal vaccination is recommended for adult patients with axial spondyloarthritis (axSpA) treated with biological drugs, since 2014, little is known about the vaccination status of this specific patient population. This study assessed their vaccination status as part of a larger online survey by the ankylosing spondylitis association of Switzerland (SVMB). Out of 1560 who participated in the survey, 834 (53.5%) were eligible for the analysis. Vaccine coverage was low at 32.5% (271/834). Women and patients who got a flu shot every year were more likely to be covered. Age was negatively associated with being vaccinated. Most (54.2%; 147/271) were vaccinated by their general practitioner. Almost two-thirds of those who had not received the vaccine stated that it had not been offered to them (64.1%; 302/471). In summary, the vaccination coverage is low, but might be increased if the vaccine was offered systematically by general practitioners and specialists.

Keywords: Adults; AxSpA; Coverage; Pneumococcal vaccine; Survey.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Axial Spondyloarthritis*
  • Female
  • Humans
  • Spondylitis, Ankylosing* / drug therapy
  • Switzerland / epidemiology
  • Vaccination
  • Vaccines* / therapeutic use


  • Vaccines